Want to see IN:TARSONS full AI Analyst Report?
TARSONS Stock Chart & Stats
₹312.55
₹8.15(2.61%)
At close: 4:00 PM EDT
₹312.55
₹8.15(2.61%)
Day’s Range― - ―
52-Week Range₹164.15 - ₹382.00
Previous CloseN/A
Volume208.60K
Average Volume (3M)2.32K
Market Cap
₹16.72B
Enterprise Value₹19.86K
Total Cash (Recent Filing)₹252.56M
Total Debt (Recent Filing)₹3.93B
Price to Earnings (P/E)116.5
Beta0.89
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.70
Shares Outstanding53,206,280
10 Day Avg. Volume1,556
30 Day Avg. Volume2,322
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.51
Price to Sales (P/S)2.27
P/FCF Ratio-134.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)₹4.88B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueTarsons’ core business is manufacturing frequently reordered lab consumables (e.g., pipette tips, tubes, vials). That recurring, usage-driven revenue model creates predictable baseline demand and repeat purchases from labs and hospitals, supporting steady topline over a multi-month horizon.
In-house Manufacturing And Broad SKU OfferingOwning manufacturing and offering a wide range of labware gives Tarsons control over supply, quality, and margins while enabling cross-selling. This structural capability reduces reliance on external suppliers, supports fill rates for institutional customers, and helps protect gross margins over the medium term.
Positive Operating Cash Flow TrendImproving operating cash flow signals the core business is generating cash from operations despite investment and FCF deficits. Sustained positive OCF supports working capital, funds ongoing production needs, and provides a foundation for deleveraging or targeted capex over the next several quarters.
Bears Say
Rising LeverageA meaningful uptick in debt raises financial risk if earnings remain weak. Higher leverage increases interest burden and reduces flexibility for capex or acquisitions; absent a clear, sustained earnings rebound, the debt trajectory could pressure liquidity and returns over the medium term.
Persistent Negative Free Cash FlowSustained negative free cash flow implies capex or reinvestment outstrips cash from operations, forcing external financing or balance-sheet draws. Over months, this can constrain strategic flexibility, raise refinancing risk, and make the company vulnerable if cash generation stalls or debt costs rise.
Weakened Profitability And Uneven RevenueEarnings and margins have declined from prior peaks while revenue growth has been uneven. Reduced operating profit and compressed ROE indicate diminished earnings power, making margin recovery and sustainable profit improvement critical to support debt and justify reinvestment decisions in coming quarters.
Tarsons Products Limited News
TARSONS FAQ
What was Tarsons Products Limited’s price range in the past 12 months?
Tarsons Products Limited lowest stock price was ₹164.15 and its highest was ₹382.00 in the past 12 months.
What is Tarsons Products Limited’s market cap?
Tarsons Products Limited’s market cap is ₹16.72B.
When is Tarsons Products Limited’s upcoming earnings report date?
Tarsons Products Limited’s upcoming earnings report date is Aug 10, 2026 which is in 3 days.
How were Tarsons Products Limited’s earnings last quarter?
Tarsons Products Limited released its earnings results on May 22, 2026. The company reported ₹0.79 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Tarsons Products Limited overvalued?
According to Wall Street analysts Tarsons Products Limited’s price is currently Overvalued.
Does Tarsons Products Limited pay dividends?
Tarsons Products Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of N/A. See more information on Tarsons Products Limited dividends here
What is Tarsons Products Limited’s EPS estimate?
Tarsons Products Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tarsons Products Limited have?
Tarsons Products Limited has 53,206,280 shares outstanding.
What happened to Tarsons Products Limited’s price movement after its last earnings report?
Tarsons Products Limited reported an EPS of ₹0.79 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.83%.
Which hedge fund is a major shareholder of Tarsons Products Limited?
Currently, no hedge funds are holding shares in IN:TARSONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tarsons Products Limited
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features disposable plastic labware, centrifuge and cryogenic equipment, liquid handling systems, and safety products. Its comprehensive catalog further encompasses items such as bottles, carboys, measuring cylinders, cell culture products, electrophoresis apparatus, microscopy and microbiology tools, vacuum desiccators, mini coolers, cryo boxes, beakers, test tube racks, pipette tips, petri dishes, centrifuge tubes, cryogenic and storage vials, Pasteur pipettes, and vortex mixers, among many others. These offerings are vital for research and applications across various scientific disciplines including molecular biology, cell culture, genomics, proteomics, and immunology.
Technical Analysis
Krebs Biochemicals & Industries Ltd.
―
Poly Medicure Limited
―
Vimta Labs Limited
―
Zim Laboratories Ltd.
―
Fischer Medical Ventures Ltd
―